创新药ETF天弘（517380）跟踪恒生沪港深创新药精选50指数，汇聚中国硬核创新药力量、新质生产力 代表，全面覆盖临床前研究至商业化全产业链，一键布局A股+港股创新药及CXO龙头企业。 1月12日，A股、港股市场携手走强，创新药概念在连续几日反弹后盘中出现震荡；恒生沪深港创新药 精选50指数截至发稿下跌0.63%，石药集团、百济神州、博腾股份等成分股小幅上涨。 稍微拉长时间来看，2026开年以来，截至1月9日收盘，恒生沪深港创新药精选50指数已累计反弹超 10%。 相关ETF中，创新药ETF天弘（517380）盘中交投活跃，截至发稿成交额超4000万元，溢折率0.78%， 溢价交易明显。 值得一提的是，Wind数据显示，该ETF近几日获资金持续布局，1月7日至9日连续获资金净流入，累 计"吸金"超1.7亿元。 消息面上，政策层面进一步加大对创新药的力挺。据媒体报道，国家药监局局长李利日前在全国药品监 督管理工作会议上介绍，2026年国家药监局将精准施策，重点推进多项工作。对新机制、新靶点创新 药，在沟通交流、临床试验、注册申报、审评审批全链条强化服务支持，助力创新药"中国首发"。 中泰证券指出，从基本面来看 ...

1月9日，博腾股份涨2.61%，成交额3.03亿元。两融数据显示，当日博腾股份获融资买入额3088.40万 元，融资偿还2466.30万元，融资净买入622.10万元。截至1月9日，博腾股份融资融券余额合计3.64亿 元。 融资方面，博腾股份当日融资买入3088.40万元。当前融资余额3.64亿元，占流通市值的2.61%，融资余 额低于近一年30%分位水平，处于低位。 融券方面，博腾股份1月9日融券偿还200.00股，融券卖出0.00股，按当日收盘价计算，卖出金额0.00 元；融券余量1.02万股，融券余额26.11万元，低于近一年20%分位水平，处于低位。 资料显示，重庆博腾制药科技股份有限公司位于重庆市北碚区云图路7号，成立日期2005年7月7日，上 市日期2014年1月29日，公司主营业务涉及化学原料药CDMO业务、化学制剂CDMO业务和生物CDMO 业务(包括基因疗法和细胞疗法)。主营业务收入构成为：临床后期及商业化业务66.81%，临床早期业务 25.76%，新兴业务7.11%，其他(补充)0.32%。 截至12月19日，博腾股份股东户数4.34万，较上期减少1.75%；人均流通股11484股，较上 ...

证券日报网讯1月8日，博腾股份（300363）在互动平台回答投资者提问时表示，公司将结合财务核算结 果，根据深交所相关业务规则及时履行信息披露义务，具体的业绩预计情况请以公司法定公告为准。 ...

证券日报网讯1月8日，博腾股份（300363）在互动平台回答投资者提问时表示，公司秉持长期发展理 念，滚动制定战略发展规划，围绕核心业务深耕、市场拓展及能力升级稳步推进，相关重大经营信息请 以公司法定信息披露为准。 ...

证券日报网讯1月8日，博腾股份（300363）在互动平台回答投资者提问时表示，公司将在2025年年度报 告中披露截至2025年12月31日股东户数，请以届时法定披露信息为准。 ...

每经AI快讯，博腾股份发布公告称，2026年1月5日，博腾股份接受长江证券等投资者调研，公司董事 会秘书、副总经理皮薇等人参与接待，并回答了投资者提出的问题。 （记者 张明双） 每经头条（nbdtoutiao）——原指导价34.99万的宝马裸车价22.5万元，多家车企还补贴购置税！2026开 年车市火爆，销售从早到晚忙到没空吃饭 ...

2026 年度医药策略观点更新 20260105 摘要 医药板块经历 2025 年调整后，机构持仓和估值均处于左侧布局阶段， 具备向上弹性，创新药及其产业链是 2026 年确定性最强且具进攻性的 方向，受益于中国创新竞争力持续加强。 创新竞争力增强的动因包括 BD 落地、海外临床进展和商业化兑现，以 及 XDC、双抗、小核酸等新技术突破，和潜在 IPO 公司登陆港股市场等 催化剂。 创新思路包括关注信达生物、博泰生物、英恩生物等核心资产，重磅数 据读出或潜在 BD 带来的短期催化剂，以及 XDC、双抗、小核酸等新技 术方向。 创新产业链全面复苏，CDMO 订单与业绩从 2024 年开始复苏，2025 年进一步全面复苏，预计 2026 年持续，凯莱英与博腾等公司具有较高 估值性价比。 内需复苏趋势明确，2025 年逐季度加强，驱动力包括国内创新 BD 创新 高、一级市场和二级市场回暖，A 股和港股 IPO 数量增加，推动一级市 场融资触底反弹。 Q&A 2026 年医药行业的投资机会主要集中在哪些方面？ 2026 年医药行业依然充满投资机会，主要集中在全球有竞争力的资产，包括 创新药、创新药产业链和高端制造。同 ...

Q5：细胞基因治疗业务今年的情况如何？是否有海外客户？ A5：2025 年，博腾生物整体业务开展符合预期，在多个业务领 域均实现突破，包括获得商业化工艺变更阶段的 CMC 项目、完 成首个 in vivo CAR 慢病毒项目工艺开发及三批 GMP 批次生 产，签署多个慢病毒/mRNA-tLNP 的 in vivo CAR-T 管线项目。 博腾生物已经在美国、欧洲、韩国等海外市场取得突破。 Q6：如何看待 in vivo CAR-T？ A6：In vivo CAR-T 为未来 CGT 商业化现货型产品打开了一种 思路和可能，但是目前仍在早期阶段，在技术成熟度、安全性 等方面仍需要验证。 证券代码：300363 证券简称：博腾股份 博腾股份投资者关系活动记录表 编号：00120260105 | | ■特定对象调研 □分析师会议 | | --- | --- | | 投资者关系活动类 | □媒体采访 □业绩说明会 | | 别 | □新闻发布会 □路演活动 | | | □现场参观 □电话通讯 | | | □其他 | | 参与单位名称及人 | 长江证券：万梦蝶、刘长洪；长江证券自营：彭仲杄；兴银基 | | 员姓名 | 金 ...

Investment Rating - The industry investment rating is "Outperform the Market," indicating an expected performance that exceeds the market by more than 5% over the next six months [29]. Core Insights - The report highlights that the national government will continue to support the renewal of medical equipment in 2026, which is expected to drive demand in the medical device sector. The focus is on high-end equipment and companies with significant performance improvements and international expansion, such as Mindray Medical, United Imaging, Aohua Endoscopy, and Kaili Medical [3]. - The report emphasizes the optimization of application conditions and review processes for equipment renewal projects, aiming to lower investment thresholds and enhance support for small and medium-sized enterprises [3]. - The ongoing policy for equipment renewal is anticipated to sustain a favorable bidding environment for medical devices, with a gradual improvement in performance as inventory clears [3]. Summary by Sections Industry Overview - The report discusses the government's announcement on December 30, 2025, regarding large-scale equipment renewal and the inclusion of various sectors, including healthcare, in the support framework for 2026 [3]. - It outlines the measures to improve the application process for equipment renewal, including stricter requirements for equipment depreciation and minimum usage periods [3]. Investment Opportunities - The report suggests focusing on companies that are expected to show significant performance improvements and have a leading international presence in the medical device sector [3]. - Specific companies recommended for investment include Mindray Medical, United Imaging, Aohua Endoscopy, and Kaili Medical, which are well-positioned to benefit from the anticipated demand for high-end medical equipment [3]. Market Performance - The medical sector has experienced a decline, with a reported drop of 2.06% in the last week, ranking 25th among 28 industries [8][18]. - The report notes that the medical device market is under pressure in the short term due to policy impacts, but improvements are expected as companies innovate and expand internationally [5].

Group 1: Core Insights - The report maintains a strong market rating for the pharmaceutical industry, indicating a clear upward trend driven by recovering demand and improved performance in the CXO sector [1][2] - The CXO sector has shown significant stock price increases, with some companies experiencing nearly 100% growth since the beginning of 2025, driven by the innovative drug market and a recovery in orders [3][6] Group 2: CXO Sector Analysis - The CXO sector's overall revenue increased by 11.8% year-on-year in the first three quarters of 2025, with a notable profit increase of 58.1% [13] - External demand for CXO services has rebounded, with significant order growth from leading CDMO companies, indicating a clear recovery trend [22][31] - Internal demand for CXO services has lagged behind external demand, but there are signs of strong growth in domestic innovative drug projects and increased investment in the domestic market [3][22] Group 3: Life Sciences Upstream - The life sciences upstream sector has seen a 37.7% increase in stock prices year-to-date, outperforming the pharmaceutical and biotechnology index by 18% [3] - Revenue for the upstream sector increased by 8.8% year-on-year in the first three quarters of 2025, with net profit rising by 27.7% [3] Group 4: Investment Recommendations - The report suggests a strategic investment focus on companies such as WuXi AppTec, WuXi Biologics, and Tigermed, while also highlighting more flexible investment options like Zhaoyan New Drug and Nossan [3]